| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
16,076 |
13,736 |
$2.19M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
14,820 |
12,892 |
$1.50M |
| G0378 |
Hospital observation service, per hour |
2,515 |
2,066 |
$1.30M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,364 |
4,725 |
$947K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
11,171 |
9,200 |
$379K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,764 |
3,355 |
$256K |
| 97597 |
|
1,989 |
916 |
$117K |
| H2017 |
Psychosocial rehabilitation services, per 15 minutes |
1,743 |
162 |
$113K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
23,296 |
15,717 |
$107K |
| 80053 |
Comprehensive metabolic panel |
11,244 |
8,598 |
$70K |
| 71046 |
Radiologic examination, chest; 2 views |
4,288 |
3,917 |
$45K |
| 71045 |
Radiologic examination, chest; single view |
8,420 |
7,222 |
$43K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,467 |
1,333 |
$36K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
23,861 |
18,108 |
$34K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12,180 |
10,252 |
$31K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,285 |
1,219 |
$30K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
9,311 |
6,880 |
$24K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,973 |
3,561 |
$23K |
| 84484 |
|
12,261 |
7,703 |
$22K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,974 |
1,614 |
$22K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,847 |
1,679 |
$21K |
| 81001 |
|
6,608 |
5,833 |
$19K |
| 94010 |
|
330 |
316 |
$18K |
| 36591 |
|
785 |
558 |
$16K |
| 93971 |
|
103 |
97 |
$14K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,696 |
1,594 |
$11K |
| 85027 |
|
9,917 |
6,394 |
$10K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,178 |
2,869 |
$9K |
| 80061 |
Lipid panel |
1,245 |
1,118 |
$9K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
652 |
601 |
$8K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
344 |
321 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,711 |
1,389 |
$8K |
| 80076 |
|
4,727 |
4,087 |
$7K |
| A9270 |
Non-covered item or service |
24,069 |
6,159 |
$7K |
| 83690 |
|
5,406 |
4,615 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
1,039 |
922 |
$6K |
| 71250 |
|
273 |
261 |
$6K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,447 |
1,170 |
$6K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,100 |
1,120 |
$6K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,903 |
2,438 |
$6K |
| 83735 |
|
8,887 |
6,187 |
$6K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
12 |
12 |
$6K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
97 |
55 |
$6K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
136 |
127 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,481 |
2,151 |
$5K |
| 81025 |
|
972 |
872 |
$5K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
68 |
64 |
$5K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,662 |
1,499 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,201 |
1,035 |
$4K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
982 |
816 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
3,049 |
2,713 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,052 |
947 |
$4K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
1,535 |
1,062 |
$4K |
| 81003 |
|
2,650 |
2,310 |
$4K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
199 |
169 |
$4K |
| 87040 |
|
2,336 |
1,136 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,399 |
2,244 |
$3K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
588 |
519 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
19 |
12 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,024 |
2,539 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,058 |
5,388 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
354 |
327 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,035 |
759 |
$3K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
150 |
113 |
$3K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,371 |
2,897 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,321 |
885 |
$2K |
| 83880 |
|
2,374 |
2,057 |
$2K |
| 87070 |
|
169 |
148 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
378 |
235 |
$2K |
| 94726 |
|
268 |
262 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
652 |
605 |
$2K |
| J1756 |
Injection, iron sucrose, 1 mg |
49 |
24 |
$2K |
| 97162 |
|
177 |
164 |
$2K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,136 |
608 |
$2K |
| 94729 |
|
341 |
335 |
$1K |
| 86140 |
|
1,331 |
1,111 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
81 |
76 |
$1K |
| 93970 |
|
19 |
17 |
$1K |
| 94760 |
|
2,624 |
1,816 |
$1K |
| 83605 |
|
3,130 |
2,343 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
122 |
67 |
$1K |
| 85610 |
|
2,857 |
2,409 |
$951.61 |
| 94060 |
|
26 |
26 |
$930.60 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
41 |
40 |
$832.27 |
| 73630 |
|
16 |
13 |
$811.29 |
| 73030 |
|
63 |
50 |
$735.16 |
| 90715 |
|
26 |
26 |
$719.63 |
| 85007 |
|
2,416 |
1,795 |
$644.42 |
| 85379 |
|
1,213 |
1,106 |
$607.61 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
138 |
120 |
$584.25 |
| 80050 |
General health panel |
36 |
28 |
$562.91 |
| 94799 |
|
922 |
605 |
$560.96 |
| 87077 |
|
1,611 |
1,021 |
$556.12 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13 |
12 |
$511.66 |
| 87186 |
|
1,753 |
1,237 |
$491.80 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
66 |
51 |
$453.43 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
355 |
325 |
$451.47 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,583 |
1,966 |
$417.46 |
| 85730 |
|
1,174 |
1,031 |
$411.25 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
40 |
28 |
$371.32 |
| 74018 |
|
25 |
24 |
$360.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,549 |
1,413 |
$327.59 |
| 82550 |
|
540 |
476 |
$325.30 |
| 86850 |
|
1,313 |
1,003 |
$289.52 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
40 |
28 |
$278.31 |
| 86803 |
|
13 |
13 |
$272.87 |
| 90686 |
|
44 |
43 |
$269.76 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
542 |
428 |
$253.28 |
| G0008 |
Administration of influenza virus vaccine |
88 |
75 |
$246.96 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
129 |
112 |
$184.48 |
| J1644 |
Injection, heparin sodium, per 1000 units |
567 |
296 |
$182.52 |
| J1940 |
Injection, furosemide, up to 20 mg |
137 |
100 |
$154.49 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
48 |
38 |
$147.51 |
| 86900 |
|
1,361 |
1,047 |
$127.01 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
171 |
154 |
$112.24 |
| 82728 |
|
130 |
102 |
$96.80 |
| 72020 |
|
13 |
12 |
$95.00 |
| 86901 |
|
1,339 |
1,029 |
$87.59 |
| J3490 |
Unclassified drugs |
114 |
71 |
$69.92 |
| 82607 |
|
83 |
72 |
$60.72 |
| 90694 |
|
13 |
13 |
$59.75 |
| 85652 |
|
181 |
162 |
$57.97 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
13 |
13 |
$53.28 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
801 |
695 |
$51.84 |
| 84145 |
|
44 |
38 |
$49.03 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
475 |
371 |
$48.17 |
| 84702 |
|
13 |
12 |
$39.00 |
| 84466 |
|
114 |
101 |
$30.40 |
| 85651 |
|
262 |
227 |
$29.26 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
19 |
13 |
$27.89 |
| J3480 |
Injection, potassium chloride, per 2 meq |
24 |
12 |
$24.69 |
| 97166 |
|
28 |
26 |
$24.40 |
| 84100 |
|
239 |
182 |
$24.21 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
14 |
12 |
$22.87 |
| 83615 |
|
78 |
66 |
$22.32 |
| 97116 |
|
51 |
39 |
$18.40 |
| J2060 |
Injection, lorazepam, 2 mg |
148 |
125 |
$13.69 |
| 83540 |
|
113 |
101 |
$11.40 |
| 87205 |
|
155 |
135 |
$3.46 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
12 |
12 |
$3.01 |
| 84132 |
|
16 |
12 |
$0.00 |
| 73564 |
|
31 |
25 |
$0.00 |
| 82746 |
|
13 |
12 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
12 |
12 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
83 |
73 |
$0.00 |
| 84439 |
|
48 |
25 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
66 |
60 |
$0.00 |
| 96367 |
|
22 |
12 |
$0.00 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
23 |
12 |
$0.00 |
| 87641 |
|
12 |
12 |
$0.00 |
| 90662 |
|
21 |
12 |
$0.00 |